1-3 of 3
Guy Gammon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P3-08-19: Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3Kα-H1047R, in mutant selected solid tumors including breast cancer

Free
Samuel Agresta, Alexander Spira, Andreas Varkaris, Seock-Ah Im, Peter Kabos, Ramon Yarza, Yeon Hee Park, Kevin Litwiler, Guy Gammon, Amy Heim, Brian Tunquist, Robbie Alton, Duncan Walker
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (12_Supplement): P3-08-19.
https://doi.org/10.1158/1557-3265.SABCS24-P3-08-19
Published: 13 June 2025
View articletitled, Abstract P3-08-19: Preliminary results from PIKture-01, a First-in-Human Study of OKI-219, a mutant selective inhibitor of PI3Kα-H1047R, in mutant selected solid tumors including breast cancer
Journal Articles

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Free
Todd M. Cooper, Jeannette Cassar, Elena Eckroth, Jemily Malvar, Richard Sposto, Paul Gaynon, Bill H. Chang, Lia Gore, Keith August, Jessica A. Pollard, Steven G. DuBois, Lewis B. Silverman, Javier Oesterheld, Guy Gammon, Daniel Magoon, Colleen Annesley, Patrick A. Brown
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16): 4014–4022.
https://doi.org/10.1158/1078-0432.CCR-15-1998
Published: 14 August 2016
View articletitled, A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Open the PDF for A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study in another window
Includes: Supplementary data
Journal Articles

Maintenance Biotherapy for Metastatic Melanoma with Interleukin-2 and Granulocyte Macrophage-Colony Stimulating Factor Improves Survival for Patients Responding to Induction Concurrent Biochemotherapy

Free
Steven J. O’Day, Peter D. Boasberg, Lawrence Piro, Timothy S. Kristedja, He-Jing Wang, Maureen Martin, Regina Deck, Patricia Ames, Kelly Shinn, Hannah Kim, Patricia Fournier, Guy Gammon
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 2775–2781.
Published: 01 September 2002
View articletitled, Maintenance Biotherapy for Metastatic Melanoma with Interleukin-2 and Granulocyte Macrophage-Colony Stimulating Factor Improves Survival for Patients Responding to Induction Concurrent Biochemotherapy
Open the PDF for Maintenance Biotherapy for Metastatic Melanoma with Interleukin-2 and Granulocyte Macrophage-Colony Stimulating Factor Improves Survival for Patients Responding to Induction Concurrent Biochemotherapy in another window